Reneo Pharmaceuticals Inc
RPHM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$907.62M
Close$
$0.87
95.2% downside
Current Fair Value
95.2% downsideOvervalued by 95.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $907.62 Million |
|---|---|
| Enterprise Value | $742.04 Million |
| Earnings per Share | $-4.4 |
| Beta | 0.22 |
| Outstanding Shares | 49,869,177 |
Return
| Return on Equity | -8.92% |
|---|---|
| Return on Assets | -8.56% |
| Return on Invested Capital | -35.98% |
Valuation & Multiples
| P/E Ratio | -5.21 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 6.07 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.96 |
| Enterprise Value to Net Income | -49 |
| Total Debt to Enterprise | -0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 6, 2025
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Reneo Pharmaceuticals Inc
18 employees
CEO: Nicholas A. Saccomano
Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produc...